CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT) today announces a license agreement with Bayer CropScience AG, headquartered in Monheim, Germany that grants exclusive, worldwide rights in the field of plants to a certain Sirtris technology that contributes to cellular life span extension and stress resistance. In return, Sirtris will receive an initial up-front and future success bound milestone payments. Further financial terms were not disclosed.
